Published in Vaccine Weekly, August 30th, 2000
Abgenix, Inc., researchers presented their findings at the 36th Annual Meeting of the American Society of Clinical Oncology, held in New Orleans, Louisiana.
Epidermal growth factor receptors (EGFr) are reportedly the target of ABX-EGF. "Patients overexpressing EGFr on their tumor cells have been reported to be associated with a poor clinical prognosis," Xiao-Dong Yang and co-investigators stated.
In cancer cell lines that express EGFr, investigators found...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.